Ventus Raises $100m To Take First Novel Compounds Into Clinic

Company Quiet About Initial Targets, Except For NLRP3

 
• By Mandy Jackson

Ventus raised $60m in series A venture capital 10 months ago when it had just one technology platform. It now has two platforms, five drug development programs and $100m in series B cash.

Virtual business assistant illustration
Ventus raised $100m to fuel its technology platform and small molecule pipeline growth • Source: Shutterstock

More from Financing

More from Business